Announced on September 10, 2025, Biocon Limited, a global biopharmaceutical company, has opened its inaugural U.S. manufacturing plant in Cranbury, New Jersey. The facility marks a significant milestone for the company and is owned entirely by Biocon Limited. With the BSE code 532523 and listed on the NSE as BIOCON, this new manufacturing site in the U.S. signifies Biocon's commitment to innovation and expansion into the American market.